Zimmer Biomet, a leading orthopedic medical device company, expressed confidence in a strong market comeback in 2025 at the JP Morgan Healthcare Conference in San Francisco. Following a challenging 2024, marked by complications with a new enterprise resource planning (ERP) system implementation that impacted revenue and stock price, the company anticipates significant growth driven by six recent product launches.
Table Content:
New Product Launches to Fuel Growth
CEO Ivan Tornos acknowledged recent market share losses in the hip and knee replacement sector to competitors like DePuy Synthes. However, he emphasized Zimmer Biomet’s ongoing turnaround, highlighting consecutive mid-single-digit revenue growth over the past three years, with hips and knees comprising approximately 68% of total revenue. The company reported a 4% year-over-year increase in net sales to $1.8 billion in its Q3 2024 financial results.
The six new products launched in the US in 2024, poised for “full launch mode” in 2025, include the Persona Revision Knee System, the HAMMR Automated Hip Impaction System, and the Oxford Cementless Partial Knee System. These additions are expected to complete Zimmer Biomet’s portfolio and drive market leadership.
Oxford Cementless Knee System: A Key Driver for US Market
Zimmer Biomet anticipates that the Oxford Cementless Partial Knee System, designed for unilateral knee procedures for patients with osteoarthritis or avascular necrosis, will be a flagship product in 2025. Available in Europe since 2004, the system boasts the highest joint survivorship registry in the UK, indicating strong potential for success in the rapidly growing US cementless knee market.
Persona Revision Knee System: European Expansion Expected
Beyond the US, Zimmer Biomet is optimistic about the upcoming European launch of the Persona Revision Knee System. Since its US approval in 2019, the system has generated over $2 billion in gross sales, solidifying its position as the leading revision system in the country. The company expects a rapid uptake in the European market.
Future of Hip and Knee Replacement
Looking ahead to 2030 and beyond, Tornos shared Zimmer Biomet’s vision for the hip and knee replacement market, which the company projects to grow at approximately 4.2%. He envisions a future where cartilage restoration replaces cartilage replacement with implants and where data-driven personalization will revolutionize surgical treatment planning and prediction of osteoarthritis. This forward-thinking approach underscores Zimmer Biomet’s commitment to innovation and leadership in the orthopedic field.
Conclusion
Zimmer Biomet’s positive outlook for 2025, fueled by new product launches and a focus on innovation, signals a strong potential for market share recovery and continued growth in the orthopedic device sector. The company’s strategic investments in research and development, coupled with its commitment to personalized medicine, position it for long-term success in a dynamic and evolving market.
